U.S. Markets closed

Catalyst Biosciences Inc (CBIO) Files 10-K for the Fiscal Year Ended on December 31, 2018

- By insider

Catalyst Biosciences Inc (CBIO) files its latest 10-K with SEC for the fiscal year ended on December 31, 2018. Catalyst Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is engaged in creating and developing novel medicines to address serious medical conditions. Catalyst Biosciences Inc has a market cap of $93.880 million; its shares were traded at around $7.86 with and P/S ratio of 110.75. Catalyst Biosciences Inc had annual average EBITDA growth of 33.50% over the past five years.

For the latest fiscal year the company reported a revenue of $0.01 million, a decrease of 99.4% from the previous year. For the last five years Catalyst Biosciences Inc had an average revenue decline of 51.8% a year.

The reported loss per diluted share was $2.68 for the year, compared with the loss per share of $269.849 in the previous year. The Catalyst Biosciences Inc had an operating margin of -563700%, compared with the operating margin of -2143.61% a year before. The 10-year historical median operating margin of Catalyst Biosciences Inc is -287.54%. The profitability rank of the company is 1 (out of 10).

At the end of the fiscal year, Catalyst Biosciences Inc has the cash and cash equivalents of $31.2 million, compared with $14.5 million in the previous year. The company had no long term debt. Catalyst Biosciences Inc has a financial strength rank of 8 (out of 10).

At the current stock price of $7.86, Catalyst Biosciences Inc is traded at 976.7% premium to its historical median P/S valuation band of $0.73. The P/S ratio of the stock is 110.75, while the historical median P/S ratio is 10.28. The stock lost 72.25% during the past 12 months.

For the complete 20-year historical financial data of CBIO, click here.

This article first appeared on GuruFocus.